Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravir https://ift.tt/eA8V8J

Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI).

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3lrEq8M
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.